Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia

Journal of Pediatrics

Volumn 141, Issue 2, 2002, Pages 247-252

  Muirhead, Sarah ^a,b,c   Sellers, Elizabeth A C ^a,b,c   Guyda, Harvey ^a,b,c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b Department of Pediatrics and Child Health ^*  (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; GLUCOCORTICOID; HYDROXYPROGESTERONE; PRASTERONE;

ADOLESCENT; ANDROGEN BLOOD LEVEL; ARTICLE; BODY HEIGHT; BONE AGE; CHILD; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC PREDISPOSITION; GENETIC RISK; GROWTH RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBERTY; RETROSPECTIVE STUDY; SALT LOSING NEPHRITIS; TREATMENT OUTCOME;

EID: 0036694879     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2002.126601     Document Type: Article

References (30)

1. Van Wyk JJ, Gunther DF, Ritzen EM, Wedell A, Cutler GB Jr, Migeon CJ, et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81:3180-90.
2. Gunther DF, Bukowski TP, Ritzen EM, Wedell A, Van Wyk JJ. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: pre- and postoperative studies. J Clin Endocrinol Metab 1997;82:3324-7.
3. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85:1114-20.
4. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB Jr. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81: 3535-9.
5. Quintos JB, Vogiatzi MG, Harbison MD, New MI. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86:1511-7.
6. Ghali I, David M, David L. Linear growth and pubertal development in treated congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1977; 6:425-36.
7. David M, Sempe M, Blanc M, Nicolino M, Forest MG, Morel Y. Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Arch Pediatr 1994;1:363-7.
8. DiMartino-Nardi J, Stoner E, O'Connell A, New MI. The effect of treatment of final height in classical congenital adrenal hyperplasia (CAH). Acta Endocrinol Suppl (Copenh) 1986;279: 305-14.
9. Young MC, Hughes IA. Response to treatment of congenital adrenal hyperplasia in infancy. Arch Dis Child 1990; 65:441-4.
10. Urban MD, Lee PA, Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Engl J Med 1978;299:1392-6.
11. Clayton GW. Patterns of growth from birth to maturity in infants and children with congenital adrenal hyperplasia. Acta Endocrinol Suppl (Copenh) 1986; 279:295-304.
12. Kirkland RT, Keenan BS, Holcombe JH, Kirkland JL, Clayton GW. The effect of therapy on mature height in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978;47:1320-4.
13. Gargantini L, Calzi P, Brunelli V, Braggion F, Chiumello G. Growth and pubertal development in males with adreno-genital syndrome. Pediatr Med Chir 1989;11:597-602.
14. Lim YJ, Batch JA, Warne GL. Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. J Paediatr Child Health 1995;31:222-7.
15. Yu AC, Grant DB. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood. Acta Paediatr 1995; 84:899-903.
16. Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: an analysis of the factors influencing adult height. Pediatr Res 1997; 41:30-3.
17. Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. Clin Endocrinol (Oxf) 1997;46: 327-32.
18. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R, Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001;138:26-32.
19. Klingensmith GJ, Garcia SC, Jones HW, Migeon CJ, Blizzard RM. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977;90:996-1004.
20. Brook CG. The management of classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1990;33:559-67.
21. Soliman AT, AlLamki M, AlSalmi I, Asfour M. Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metabolism 1997;46:513-7.
22. Silva IN, Kater CE, Cunha CF, Viana MB. Randomised controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child 1997;77:214-8.
23. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997;82: 3926-9.
24. Linder BL, Esteban NV, Yergey AL, Winterer JC, Loriaux DL, Cassorla F. Cortisol production rate in childhood and adolescence. J Pediatr 1990;117:892-6.
25. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 1993;76:1505-10.
26. Appan S, Hindmarsh PC, Brook CG. Monitoring treatment in congenital adrenal hyperplasia. Arch Dis Child 1989;64:1235-9.
27. Gasparini N, Di Maio S, Salerno M, Argenziano A, Franzese A, Tenore A. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency). Horm Res 1997;47:17-22.
28. Rasat R, Espiner EA, Abbott GD. Growth patterns and outcomes in congenital adrenal hyperplasia: effect of chronic treatment regimens. N Z Med J 1995;108:311-4.
29. Frisch H, Parth K, Schober E, Swoboda W. Circadian patterns of plasma cortisol, 17-hydroxyprogesterone, and testosterone in congenital adrenal hyperplasia. Arch Dis Child 1981;56: 208-13.
30. Bode HH, Rivkees SA, Cowley DM, Pardy K, Johnson S. Home monitoring of 17-hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples. J Pediatr 1999;134:185-9.